Synthes partners with Materialise in Cranio-Maxillofacial surgery

Synthes, Inc. (SWX: SYST.VX), a leading global medical device company in orthopaedic trauma, spine, and cranio-maxillofacial (CMF), and Materialise NV, a leader in the field of rapid industrial and medical prototyping and innovative software solutions, announced an exclusive partnership for the development and distribution of Materialise's solutions for Cranio-Maxillofacial (CMF) surgery.

Under the partnership, Materialise will provide pre-operative planning services directly to the surgeon via interactive, web-based collaboration tools, and will fabricate intra-operative guides and anatomical models. Synthes will distribute these intra-operative guides and models and continue to deliver patient specific surgical implants.

The combination of Materialise's continuing commitment to research and development in the field of pre-operative planning and Synthes' track record as a leader in medical device manufacturing, including patient-specific implants for CMF surgery, makes this an excellent partnership for both companies.

Michel Orsinger, President and CEO of Synthes, commented on the partnership: "This partnership will allow Synthes to continue our mission to improve patient care by optimizing operating room time and by improving the precision of the surgery. Materialise and Synthes share the same core values: a desire to assist the patient and surgeon, as well as quality, innovation, education, and integrity. The partnership will reinforce our position as an innovator in CMF."

Wilfried Vancraen, General Manager, Materialise, is delighted with the partnership: "This partnership supports Materialise's mission for a better and healthier world, and the technology we offer adds tremendous value through patient-specific solutions in the complex field of CMF surgery. With Synthes' emphasis on surgeon education and their ability to offer our planning services and products globally we have found the right partner in Synthes as the global leader in CMF to be able to take this forward-thinking technology to the next level."

For more information visit: or

Restrictions Subject to US Securities Law

Synthes, Inc. management believes certain statements in this media release may constitute "Forward-Looking Statements" within the meaning of the "Private Securities Litigation Reform Act of 1995". These statements include but are not limited to those with respect to the potential for Synthes to offer new products and market existing ones, as well as the expected sales and sales growth of Synthes. These statements are made on the basis of management's views and assumptions regarding future events and business performance as of the time the statements are made. Actual results may differ materially from those expressed or implied. Such differences may result from the ability of Synthes to successfully develop and introduce new products and services and market existing products and services in a competitive marketplace and changes in the economic conditions that may affect the performance of the operations of Synthes. In addition, changes in competitive conditions and regulatory developments may affect future business performance, and changing market conditions may affect the valuation of Synthes securities. In addition, it should be noted that past financial and operational performance of the company is not necessarily indicative of future financial and operational performance. Synthes undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The securities of Synthes have been offered and sold outside the United States and have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"). Such securities may not be offered, sold or transferred in the U.S. or to U.S. Persons (as defined in the regulations of the Securities Act), except pursuant to a registration statement filed under the Securities Act or under an applicable exemption under the Securities Act. Hedging transactions involving such securities may not be conducted unless in compliance with the Securities Act. The Synthes securities are deemed "Restricted Securities" as that term is defined in Rule 144 under the Securities Act.

Read 3951 times

Rate this item
(1 Vote)

Copyright © 2019 Prototype Today ®. All rights reserved.

|   Privacy Policy |   Terms & Conditions |   Contact Us |

All trademarks and registered trademarks are the property of their respective owners.

Additive Manufacturing Today